S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
WSC Sports Was Built on a Love for Sports. It Changed The Entire Game.
Ride These Railroad Stocks for Growth and Income
The Next Big Crisis Is Here (Ad)
ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
Microsoft’s Comeback Is Now Underway
The Next Big Crisis Is Here (Ad)
KLA Corporation: Strength In A Troubled Semi-Market
Can Amazon Recover Amid Tech Stock Sell-off?
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
WSC Sports Was Built on a Love for Sports. It Changed The Entire Game.
Ride These Railroad Stocks for Growth and Income
The Next Big Crisis Is Here (Ad)
ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
Microsoft’s Comeback Is Now Underway
The Next Big Crisis Is Here (Ad)
KLA Corporation: Strength In A Troubled Semi-Market
Can Amazon Recover Amid Tech Stock Sell-off?
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
WSC Sports Was Built on a Love for Sports. It Changed The Entire Game.
Ride These Railroad Stocks for Growth and Income
The Next Big Crisis Is Here (Ad)
ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
Microsoft’s Comeback Is Now Underway
The Next Big Crisis Is Here (Ad)
KLA Corporation: Strength In A Troubled Semi-Market
Can Amazon Recover Amid Tech Stock Sell-off?
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
WSC Sports Was Built on a Love for Sports. It Changed The Entire Game.
Ride These Railroad Stocks for Growth and Income
The Next Big Crisis Is Here (Ad)
ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
Microsoft’s Comeback Is Now Underway
The Next Big Crisis Is Here (Ad)
KLA Corporation: Strength In A Troubled Semi-Market
Can Amazon Recover Amid Tech Stock Sell-off?
NASDAQ:CCXI

ChemoCentryx - CCXI Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$51.99
$51.99
50-Day Range
$51.66
$51.99
52-Week Range
$14.95
$52.00
Volume
113 shs
Average Volume
1.68 million shs
Market Capitalization
$3.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$64.40

ChemoCentryx MarketRank™ Forecast

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
23.9% Upside
$64.40 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-1.75
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.81) to ($0.75) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.56 out of 5 stars

Medical Sector

952nd out of 1,055 stocks

Pharmaceutical Preparations Industry

469th out of 519 stocks


CCXI stock logo

About ChemoCentryx (NASDAQ:CCXI) Stock

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

Receive CCXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ChemoCentryx and its competitors with MarketBeat's FREE daily newsletter.

CCXI Stock News Headlines

AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
ChemoCentryx (NASDAQ: CCXI)
Biotech Valuations Remain In a Slump - TheStreet
See More Headlines

Receive CCXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ChemoCentryx and its competitors with MarketBeat's FREE daily newsletter.

CCXI Company Calendar

Last Earnings
11/08/2021
Today
1/28/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CCXI
CUSIP
16383L10
Employees
178
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$64.40
High Stock Price Forecast
$85.00
Low Stock Price Forecast
$52.00
Forecasted Upside/Downside
+23.9%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$-131,760,000.00
Net Margins
-357.01%
Pretax Margin
-357.01%

Debt

Sales & Book Value

Annual Sales
$32.22 million
Book Value
$4.09 per share

Miscellaneous

Free Float
65,433,000
Market Cap
$3.71 billion
Optionable
Optionable
Beta
1.22

Key Executives

  • Dr. Thomas J. Schall Ph.D. (Age 63)
    Founder, Pres, CEO & Chairman
    Comp: $1.21M
  • Ms. Susan M. Kanaya (Age 59)
    Exec. VP, Chief Financial & Admin. Officer, Sec. and Director
    Comp: $845.04k
  • Mr. Tausif  ButtMr. Tausif Butt (Age 56)
    Exec. VP & COO
    Comp: $1.01M
  • Dr. Rita I. Jain M.D. (Age 59)
    Exec. VP, Chief Medical Officer & Exec. Employee Director
    Comp: $670.7k
  • Dr. Markus J. Cappel Ph.D. (Age 61)
    Chief Bus. Officer & Treasurer
    Comp: $643.58k
  • Ms. Yi Ching Yau (Age 46)
    Sr. VP of Fin. & Principal Accounting Officer
  • Mr. William S. Slattery
    VP of Investor Relations & Corp. Communications
  • Ms. Kari E. Leetch
    Sr. VP of HR
  • Dr. Sangita Ghosh Ph.D.
    Sr. VP of Technical Operations













CCXI Stock - Frequently Asked Questions

Should I buy or sell ChemoCentryx stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CCXI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CCXI, but not buy additional shares or sell existing shares.
View CCXI analyst ratings
or view top-rated stocks.

What is ChemoCentryx's stock price forecast for 2023?

5 equities research analysts have issued 12-month price objectives for ChemoCentryx's shares. Their CCXI share price forecasts range from $52.00 to $85.00. On average, they predict the company's share price to reach $64.40 in the next twelve months. This suggests a possible upside of 23.9% from the stock's current price.
View analysts price targets for CCXI
or view top-rated stocks among Wall Street analysts.

How were ChemoCentryx's earnings last quarter?

ChemoCentryx, Inc. (NASDAQ:CCXI) issued its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.13. The biopharmaceutical company had revenue of $17.74 million for the quarter, compared to the consensus estimate of $14.70 million. ChemoCentryx had a negative trailing twelve-month return on equity of 48.52% and a negative net margin of 357.01%. During the same quarter in the prior year, the business posted ($0.35) earnings per share.

What is Thomas J. Schall's approval rating as ChemoCentryx's CEO?

21 employees have rated ChemoCentryx Chief Executive Officer Thomas J. Schall on Glassdoor.com. Thomas J. Schall has an approval rating of 58% among the company's employees. This puts Thomas J. Schall in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 44.0% of employees surveyed would recommend working at ChemoCentryx to a friend.

What other stocks do shareholders of ChemoCentryx own?
What is ChemoCentryx's stock symbol?

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

What is ChemoCentryx's stock price today?

One share of CCXI stock can currently be purchased for approximately $51.99.

How much money does ChemoCentryx make?

ChemoCentryx (NASDAQ:CCXI) has a market capitalization of $3.71 billion and generates $32.22 million in revenue each year. The biopharmaceutical company earns $-131,760,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis.

How many employees does ChemoCentryx have?

The company employs 178 workers across the globe.

How can I contact ChemoCentryx?

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The official website for the company is www.chemocentryx.com. The biopharmaceutical company can be reached via phone at (650) 210-2900, via email at investor@chemocentryx.com, or via fax at 650-210-2910.

This page (NASDAQ:CCXI) was last updated on 1/28/2023 by MarketBeat.com Staff